Research published in Progress in Neuro-Psychopharmacology and Biological Psychiatry (page 5)

Intravenous infusion of xenon-containing liposomes generates rapid antidepressant-like effects.

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 30, 2018 Manoj P Dandekar, Tao Peng, David D McPherson et al.

Similar to ketamine, xenon gas acts as a glutamatergic N-methyl-d-aspartate receptor antagonist, but devoid of propensity to cause untoward effects. Herein, we loaded xenon gas into a liposomal carrier called xenon-containing liposomes (Xe-liposome) for systemic delivery, and investigated its effect as an antidepressant and also analyzed synaptic biomarkers including brain-derived neurotrophic...

DOI: 10.1016/j.pnpbp.2018.03.011 Full text Depression Akt Bdnf Forced swimming test +2

The acute and residual effects of escalating, analgesic-range doses of ketamine on driving performance: A simulator study.

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 30, 2018 Amie C Hayley, Maja Green, Luke A. Downey et al.

Ketamine hydrochloride elicits potent psychotomimetic and neurobehavioural effects which make it incompatible with driving; however, the direct effect on driving performance is yet to be assessed. Using an open label, within-subjects protocol, 15 males and 5 females (mean age = 30.8 years) were administered three fixed, stepwise increasing sub-anaesthetic doses of intravenous (IV) ketamine...

DOI: 10.1016/j.pnpbp.2018.05.015 Full text Ketamine Accident Driving Risk +1

Chronic administration of amphetamines disturbs development of neural progenitor cells in young adult nonhuman primates.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 13, 2018 Rahul R Dutta, Michael A. Taffe, Chitra D Mandyam

The detrimental effects of amphetamines on developmental stages of NPCs are limited to rodent brain and it is not known if these effects occur in nonhuman primates which are the focus of the current investigation. Young adult rhesus macaques either experienced MDMA only, a combination of amphetamines (MDMA, MDA and methamphetamine) or no amphetamines (controls) and hippocampal tissue was...

DOI: 10.1016/j.pnpbp.2018.03.023 Full text MDMA Granule cell neurons Hippocampus Ki-67 +2

Ketamine-induced hypnosis and neuroplasticity in mice is associated with disrupted p-MEK/p-ERK sequential activation and sustained upregulation of survival p-FADD in brain cortex: Involvement of GABAA receptor.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 10, 2018 Glòria Salort, María Álvaro-Bartolomé, Jesús A García-Sevilla

Ketamine (KET) is an antidepressant and hypnotic drug acting as an antagonist at excitatory NMDA glutamate receptors. The working hypothesis postulated that KET-induced sleep in mice results in dysregulation of mitogen-activated protein kinases (MAPK) MEK-ERK sequential phosphorylation and upregulation of survival p-FADD and other neuroplastic markers in brain. Low (5-15 mg/kg) and high (150...

DOI: 10.1016/j.pnpbp.2018.07.006 Full text Ketamine Neuroplasticity Cerebral cortex Animals +18

MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 8, 2018 Allison A. Feduccia, Michael C Mithoefer 213 citations

MDMA-assisted psychotherapy for treatment of PTSD has recently progressed to Phase 3 clinical trials and received Breakthrough Therapy designation by the FDA. MDMA used as an adjunct during psychotherapy sessions has demonstrated effectiveness and acceptable safety in reducing PTSD symptoms in Phase 2 trials, with durable remission of PTSD diagnosis in 68% of participants. The underlying...

DOI: 10.1016/j.pnpbp.2018.03.003 Full text Amygdala Fear extinction Hippocampus MDMA-Assisted Psychotherapy +2

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry February 2, 2018 Simon Reiche, Leo Hermle, Stefan Gutwinski et al. 125 citations

Anxiety and depression are some of the most common psychiatric symptoms of patients suffering with life-threatening diseases, often associated with a low quality of life and a poor overall prognosis. 5-HT2A-receptor agonists (serotonergic hallucinogens, 'psychedelics') like lysergic acid diethylamide (LSD) and psilocybin were first investigated as therapeutic agents in the 1960s. Recently,...

DOI: 10.1016/j.pnpbp.2017.09.012 Full text Anxiety LSD Psilocybin Cancer +2

Harmine produces antidepressant-like effects via restoration of astrocytic functions.

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 3, 2017 Fengguo Liu, Jingjing Wu, Yu Gong et al.

Depression is a world-wide disease with no effective therapeutic methods. Increasing evidence indicates that astrocytic pathology contributes to the formation of depression. In this study, we investigated the effects of harmine, a natural β-carboline alkaloid and potent hallucinogen, known to modulate astrocytic glutamate transporters, on chronic unpredictable stress (CUS)-induced...

DOI: 10.1016/j.pnpbp.2017.06.012 Full text Depression Astrocyte Chronic unpredictable stress Glutamate transporter 1 +1

Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information.

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 3, 2017 Mohini Ranganathan, Rajiv Radhakrishnan, Peter H. Addy et al.

Cannabis and agonists of the brain cannabinoid receptor (CB1R) produce acute memory impairments in humans. However, the extent to which cannabinoids impair the component processes of encoding and retrieval has not been established in humans. The objective of this analysis was to determine whether the administration of Δ9-Tetrahydrocannabinol (THC), the principal psychoactive constituent of...

DOI: 10.1016/j.pnpbp.2017.06.019 Full text Cannabis Marijuana THC Cannabinoids +4

N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry November 3, 2016 Jen-Cheng Lin, Ming‐huan Chan, Mei-Yi Lee et al.

Ketamine, a dissociative anesthetic, produces rapid and sustained antidepressant effects at subanesthtic doses. However, it still inevitably induces psychotomimetic side effects. N,N-dimethylglycine (DMG) is a derivative of the amino acid glycine and is used as a dietary supplement. Recently, DMG has been found acting at glycine binding site of the N-methyl-d-aspartate receptor (NMDAR). As...

DOI: 10.1016/j.pnpbp.2016.06.002 Full text Anesthesia Forced swimming Glycine Nmda receptor +1

Hallucinatory experience as aberrant event memory formation: Implications for the pathophysiology of schizophrenia.

Progress in Neuro-Psychopharmacology and Biological Psychiatry November 3, 2016 Ralf-Peter Behrendt

If hallucinations are not fundamentally different from normal wakeful experiences, then the neural basis of hallucinations has to be essentially that of consciousness in general. The additional insight that consciousness reflects the formation (as opposed to consolidation) of event (episodic) memories links the pathophysiology of hallucinations to the hippocampus. Perceptions and...

DOI: 10.1016/j.pnpbp.2016.07.009 Full text Consciousness Episodic memory Hippocampus Schizophrenia

Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry November 3, 2016 Kristian Gaarn Du Jardin, Heidi Kaastrup Müller, Betina Elfving et al.

A single i.v. infusion of ketamine, classified as an N-methyl-d-aspartate (NMDA) receptor antagonist, may alleviate depressive symptoms within hours of administration in treatment resistant depressed patients, and the antidepressant effect may last for several weeks. These unique therapeutic properties have prompted researchers to explore the mechanisms mediating the antidepressant effects of...

DOI: 10.1016/j.pnpbp.2016.05.007 Full text Ketamine Serotonin Antidepressant Glutamate +1

Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression.

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 3, 2016 Yong‐Ku Kim, Kyoung-Sae Na

Treatment-resistant depression (TRD) causes substantial socioeconomic burden. Although a consensus on the definition of TRD has not yet been reached, it is certain that classic monoaminergic antidepressants are ineffective for TRD. One decade ago, many researchers found ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, to be an alternative to classic monoaminergic antidepressants....

DOI: 10.1016/j.pnpbp.2016.03.009 Full text Ketamine Treatment-resistant depression Glia Glutamate receptors +1

Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 16, 2016 Steven F. Grieco, Yu-yan Cheng, H. Eldar-Finkelman et al.

ABSTRACT An antidepressant dose of the rapidly‐acting ketamine inhibits glycogen synthase kinase‐3 (GSK3) in mouse hippocampus, and this inhibition is required for the antidepressant effect of ketamine in learned helplessness depression‐like behavior. Here we report that treatment with an antidepressant dose of ketamine (10 mg/kg) increased expression of insulin‐like growth factor 2 (IGF2) in...

DOI: 10.1016/j.pnpbp.2016.08.008 Full text

Effect of JWH-250, JWH-073 and their interaction on "tetrad", sensorimotor, neurological and neurochemical responses in mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 3, 2016 Andrea Ossato, Isabella Canazza, Claudio Trapella et al.

JWH-250 and JWH-073 are two synthetic cannabinoid agonists with nanomolar affinity at CB1 and CB2 receptors. They are illegally marketed within "herbal blend" for theirs psychoactive effects greater than those produced by Cannabis. Recently, we analyzed an "herbal" preparation containing a mixture of both JWH-250 and JWH-073. The present study was aimed at investigating the in vitro and in vivo...

DOI: 10.1016/j.pnpbp.2016.01.007 Full text Jwh-018 Jwh-073 Jwh-250 Microdialysis +1

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 4, 2016 Alicia Danforth, Christopher M Struble, Berra Yazar-Klosinski et al. 110 citations

The first study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014. The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population. Serious Adverse Events (SAEs)...

DOI: 10.1016/j.pnpbp.2015.03.011 Full text Ecstasy Psychotherapy Social anxiety MDMA Therapy: MDMA +13

Classic hallucinogens in the treatment of addictions.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 4, 2016 Michael P. Bogenschutz, Matthew W Johnson

Addictive disorders are very common and have devastating individual and social consequences. Currently available treatment is moderately effective at best. After many years of neglect, there is renewed interest in potential clinical uses for classic hallucinogens in the treatment of addictions and other behavioral health conditions. In this paper we provide a comprehensive review of both...

DOI: 10.1016/j.pnpbp.2015.03.002 Full text Addiction LSD Psilocybin Substance use disorder +2

Long-term effects of repeated social stress on the conditioned place preference induced by MDMA in mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 3, 2015 María P García-Pardo, M C Blanco-Gandía, M Valiente-Lluch et al.

Previous studies have demonstrated that social defeat stress increases the rewarding effects of psychostimulant drugs such as cocaine and amphetamine. In the present study we evaluated the long-term effects of repeated social defeat (RSD) on the rewarding effects of ±3,4-methylenedioxymethamphetamine (MDMA) hydrochloride in the conditioned place preference (CPP) paradigm. Adolescent and young...

DOI: 10.1016/j.pnpbp.2015.06.006 Full text MDMA Adolescence Conditioned place preference Mice +1

D-aspartate dysregulation in Ddo(-/-) mice modulates phencyclidine-induced gene expression changes of postsynaptic density molecules in cortex and striatum.

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 1, 2015 Andrea De Bartolomeis, Francesco Errico, Giuseppe Aceto et al.

N-methyl-D-aspartate receptor (NMDAR) hypofunction has been considered a key alteration in schizophrenia pathophysiology. Thus, several strategies aimed at enhancing glutamatergic transmission, included the introduction in therapy of D-amino acids, such as D-serine and D-cycloserine augmentation, have been proposed to counteract difficult-to-treat symptoms or treatment-resistant forms of...

DOI: 10.1016/j.pnpbp.2015.05.003 Full text Homer Nmdar Psd-95 Psychosis +1

3,4-Methylenedioxymethamphetamine enhances kainic acid convulsive susceptibility.

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 3, 2014 Sonia Abad, Fèlix Junyent, Carme Auladell et al.

Kainic acid (KA) causes seizures and neuronal loss in the hippocampus. The present study investigated whether a recreational schedule of 3,4-methylenedioxymethamphetamine (MDMA) favours the development of a seizure state in a model of KA-induced epilepsy and potentiates the toxicity profile of KA (20 or 30mg/kg). Adolescent male C57BL/6 mice received saline or MDMA t.i.d. (s.c. every 3h), on...

DOI: 10.1016/j.pnpbp.2014.06.007 Full text MDMA Calbindin Calretinin Kainic acid +2

Genetic dissection of the psychotomimetic effects of cannabinoid exposure.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 3, 2014 Colm M P O'Tuathaigh, Ilse Gantois, John L. Waddington

Cannabis use is an established risk factor for the development of schizophrenia and related psychotic disorders. Factors that may mediate susceptibility to the psychosis-inducing effects of cannabis include the age at onset of first cannabis use, genetic predisposition, as well as interaction with other environmental risk variables. Clinical and preclinical genetic studies provide increasing...

DOI: 10.1016/j.pnpbp.2013.11.002 Full text Cannabis Delta-9-tetrahydrocannabinol Dopamine Psychosis

Behavioral and neurochemical effects of repeated MDMA administration during late adolescence in the rat.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 3, 2014 Brittney M Cox, Mrudang M Shah, Teri Cichon et al.

Adolescents and young adults disproportionately abuse 3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'); however, since most MDMA research has concentrated on adults, the effects of MDMA on the developing brain remain obscure. Therefore, we evaluated place conditioning to MDMA (or saline) during late adolescence and assessed anxiety-like behavior and monoamine levels during abstinence. Rats...

DOI: 10.1016/j.pnpbp.2013.09.021 Full text Anxiety MDMA 3,4-methylenedioxymethamphetamine 5-hiaa +16

Is schizophrenia a dopamine supersensitivity psychotic reaction?

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 3, 2014 Mary V. Seeman, Philip Seeman

Adolf Meyer (1866-1950) did not see schizophrenia as a discrete disorder with a specific etiology but, rather, as a reaction to a wide variety of biopsychosocial factors. He may have been right. Today, we have evidence that gene mutations, brain injury, drug use (cocaine, amphetamine, marijuana, phencyclidine, and steroids), prenatal infection and malnutrition, social isolation and...

DOI: 10.1016/j.pnpbp.2013.10.003 Full text D1d2 receptor dimer D2d2 receptor dimer Dopamine release Mutation +2

The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 3, 2014 Patrick Dawson, Jolanta Opacka-Juffry, James D Moffatt et al.

5-APB, commonly marketed as 'benzofury' is a new psychoactive substance and erstwhile 'legal high' which has been implicated in 10 recent drug-related deaths in the UK. This drug was available on the internet and in 'head shops' and was one of the most commonly sold legal highs up until its recent UK temporary ban (UK Home Office). Despite its prominence, very little is known about its...

DOI: 10.1016/j.pnpbp.2013.08.013 Full text LSD MDMA Lysergic acid diethylamide 3,4, methylenedioxymethamphetamine +17

The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 3, 2012 John Corkery, Emma Durkin, Simon Elliott et al. 105 citations

5-MeO-DALT (N,N-diallyl-5-methoxytryptamine) is a psychoactive substance, sold primarily over the Internet as a 'research chemical' or 'plant food'. Although details for the synthesis of this tryptamine have been available since 2004, its use as a hallucinogenic drug has been reported only occasionally in on-line user fora. It is controlled in only a few countries world-wide. There is little...

DOI: 10.1016/j.pnpbp.2012.05.022 Full text

Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 10, 2012 Daniel I. Brierley, Colin Davidson 133 citations

Ayahuasca is a hallucinogenic botanical mixture originating in the Amazon area where it is used ritually, but is now being taken globally. The 2 main constituents of ayahuasca are N,N-dimethyltryptamine (DMT), a hallucinogen, and harmine, a monoamine oxidase inhibitor (MAOI) which attenuates the breakdown of DMT, which would otherwise be broken down very quickly after oral consumption. Recent...

DOI: 10.1016/j.pnpbp.2012.06.001 Ayahuasca Addiction Harmine Hallucinogen +2

Papers